Michael Maris, Gilles Salles, Won Seog Kim, Tae Min Kim, Roger M Lyons, Martha Arellano, Reem Karmali, Gary Schiller, Elizabeth Cull, Camille N Abboud, Connie Batlevi, Ioannis Kagiampakis, Marlon C Rebelatto, Young Lee, Lyndon C Kirby, Fujun Wang, John Bothos, Danielle M Townsley, Amir T Fathi, Vincent Ribrag
BACKGROUND: MEDI7247 is a first-in-class antibody-drug conjugate (ADC) consisting of an anti-sodium-dependent alanine-serine-cysteine transporter 2 antibody-conjugated to a pyrrolobenzodiazepine dimer. OBJECTIVE: This first-in-human phase 1 trial evaluated MEDI7247 in patients with hematological malignancies. PATIENTS AND METHODS: Adults with acute myeloid leukemia (AML), multiple myeloma (MM), or diffuse large B-cell lymphoma (DLBCL) relapsed or refractory (R/R) to standard therapies, or for whom no standard therapy exists, were eligible...
April 29, 2024: Targeted Oncology